A032101: A PHASE 2 TRIAL OF ADT INTERRUPTION IN PATIENTS RESPONDING EXCEPTIONALLY TO AR-PATHWAY INHIBITOR IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): A-DREAM
Details
Age
Adult
Type of Study
Treatment
Locations
Rocky Mountain Regional VA Medical Center
Principal Investigator
Jessica Mcdermott, MD
Study ID
Protocol Number: 22-1383
More information available at ClinicalTrials.gov: NCT05241860
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers